What Researchers Did
Researchers conducted a long-term follow-up study to assess the safety and efficacy of hyperbaric oxygen therapy for radiation cystitis in 38 prostate cancer patients.
What They Found
High efficacy ratios for objective and subjective symptoms were observed at 2 and 4 years (79-95%), remaining stable at 75-88% after 7 years. Significant improvement in late morbidity scores was seen 11.6 years post-HBO therapy (p < 0.0005), with 74% of patients achieving nonrecurrent outcomes. Nonrecurrent patients had received 18% lower radiation dosage and started HBO 30% sooner after hematuria onset.
What This Means for Canadian Patients
Hyperbaric oxygen therapy could offer a safe and effective long-term treatment option for radiation cystitis, a debilitating side effect of prostate cancer radiotherapy. Early intervention with HBO might improve outcomes and reduce recurrence for Canadian patients experiencing this condition.
Canadian Relevance
This study has no direct Canadian connection as it was conducted in Japan.
Study Limitations
A limitation of this study is its single-center design and the absence of a control group for comparison.